FDA Approves Lucentis for the Treatment of Macular Edema
FDA approves Genentech's Lucentis
After a six-month priority review, the US Food and Drug Administration has approved a new indication for Lucentis (ranibizumab injection), developed by Genentech, a member of the Roche group. Lucentis now can be used for the treatment of macular edema following retinal vein occlusion (RVO). Lucentis was first approved by the FDA in 2006 for the treatment of neovascular (wet) age-related macular degeneration.
RVO affects more than 1 million people in the US and is the second-most common cause of vision loss because of retinal vascular disease, which can develop over a long period of time or occur suddenly. Lucentis binds to and inhibits vascular endothelial growth factor A (VEGF-A), a protein that is believed to play a critical role in neovascularism and leakage that contribute to macular swelling after RVO.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
The Future of Cleanroom Construction: How Hybrid Solutions are Changing the Game
May 14th 2025Imagine a world where cleanroom facilities—essential for pharmaceutical manufacturing, biotechnology, and high-tech industries—are built with unparalleled speed, precision, and efficiency. That world is here, thanks to the hybrid construction approach. By blending traditional stick-built methods with modular and prefabricated solutions, companies are overcoming the limitations of conventional construction while ensuring compliance with stringent industry regulations. In this interview, we explore how hybrid cleanroom construction is transforming the industry, offering faster project timelines, improved quality control, and significant cost advantages. Join us as we delve into this game-changing approach with industry experts who are leading the charge in revolutionizing cleanroom infrastructure.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
